ArticleAnnals of surgical oncology2026
Development of a Prediction Model for Skin Graft Failure Following Skin Cancer Excision: The GRAFT Score.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Developing the GRAFT Score for Skin Graft Failure After Skin Cancer Excision.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSkin grafting after skin cancer excision is a commonly performed procedure. Preoperative identification and optimization of patients at risk of graft failure can improve outcomes and healthcare cost effectiveness. This study aimed to develop and internally validate a risk assessment tool, the skin Graft Risk Assessment of Failure Tool (GRAFT) to aid risk stratification of patients undergoing skin grafting after cancer excision.
methodsA single-center retrospective cohort of 162 patients who underwent skin grafting after skin cancer excision was included. Relevant variables were assessed using univariate logistic regression. Variables demonstrating significant association were entered into multivariable modeling. Model discrimination and calibration were respectively assessed using the area under the receiver operating characteristic curve (AUC) and Hosmer-Lemeshow goodness-of-fit test. Bootstrapping was used for internal validation.
resultsAnticoagulation and cancer location demonstrated significant association with graft failure in the univariate analysis. In multivariable analysis, anticoagulation (odds ratio [OR] 6.40; 95% confidence interval [CI] 2.25-18.24) and lower body graft location (OR 3.19; 95% CI 1.21-8.45) remained independently associated with graft failure. The final model demonstrated acceptable discrimination (AUC 0.72), and the Hosmer-Lemeshow test showed no evidence of lack of fit (p = 0.87), with stable performance on bootstrap validation. The GRAFT score stratified patients into low-, intermediate-, and high-risk groups with observed failure rates of 7.5%, 26.0%, and 60.0%, respectively.
conclusionThe GRAFT score is an internally validated, simple, practical, bedside tool that estimates risks of skin graft failure after skin cancer excision, supporting clinical decision-making and patient counseling. External validation of this model is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.